Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2001-06-28
2009-02-24
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S247100, C424S236100, C514S002600, C514S008100
Reexamination Certificate
active
07494661
ABSTRACT:
Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.
REFERENCES:
patent: 5562907 (1996-10-01), Arnon
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5897579 (1999-04-01), Sanders
patent: 5989545 (1999-11-01), Foster et al.
patent: 6087327 (2000-07-01), Pearce et al.
patent: 6447785 (2002-09-01), Donovan
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6500436 (2002-12-01), Donovan
patent: 6524580 (2003-02-01), Donovan
patent: 6585970 (2003-07-01), Donovan
patent: 6716427 (2004-04-01), Donovan
patent: 6740321 (2004-05-01), Donovan
patent: 6743424 (2004-06-01), Donovan
patent: 2002/0037833 (2002-03-01), Donovan
patent: 2002/0086036 (2002-07-01), Walker
patent: 2002/0094339 (2002-07-01), Brin et al.
patent: 2003/0138640 (2003-07-01), Rische et al.
patent: 2003/0202990 (2003-10-01), Donovan et al.
patent: 2004/0018212 (2004-01-01), Aoki et al.
patent: 2004/0018214 (2004-01-01), Aoki et al.
patent: 2004/0028706 (2004-02-01), Aoki et al.
patent: 2004/0037895 (2004-02-01), Zhu
patent: 2004/0086531 (2004-05-01), Barron
patent: 2004/0086532 (2004-05-01), Donovan
patent: 2004/0115139 (2004-06-01), Katz et al.
patent: 2004/0248188 (2004-12-01), Sanders
patent: WO 95/28171 (1995-10-01), None
patent: WO 00/24419 (2000-05-01), None
patent: WO 03/000193 (2003-01-01), None
patent: WO 2004/048519 (2004-06-01), None
patent: WO 2004/076634 (2004-09-01), None
Habermann, E. et al. 1988. Tetnus toxin and Botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain. J. Neurochem. 51(2): 522-527.
Kryzhanovskil et al, Bull. Exp. Biol. Med., 1975, 77/7:732-736.
Bizzini et al, Toxicon., 1988, 26/3:309-318.
Kitamura et al, Biochimica et Biophysica Acta, 1999, 1441:1-3.
Fezza et al, Ophthalmic Plastic and Reconstructive Surgery, 2000, 16/2:101-113.
Li et al, JBC, Aug. 2001, 276/33:31394-31401.
Williamson et al, JBC, Aug. 1999, 274/35:25173-25180.
Grangette et al, Vaccine, 2002, 20:3304-3309.
Kryzhanovskii et al, Bull. Exp. Biol. Med., 1974, 76/9:1030-1033.
Ricker et al, J. Neurol. 1974, 207:155-163.
Sherwin et al, Journal of Voice, 1994, 8/1:65-69.
Horn et al, Journal of Comparative Neurology, 2000, 420:19-34.
Kryzhanovskii et al, Bull. Exp. Biol. Med., 1975, 78/11:1234-1237.
Yavin et al, JBC, 1981, 256/13:7014-7022.
Gonzalez-Forero et al, J. Neuroscience, Jan. 12, 2005, 25/2:429-417.
Gonzalez-Forero et al, J. Neurophysiol., 2003, 89:1878-1890.
Ahnert-Hilger et al, Progress in Neurobiology, May 1995, 46/1:83-96.
Gonzalez-Forero et al, NeuroReport, Mar. 26, 2001, 12/4:753-756.
Price et al, Science, May 30, 1975, 188:945-947.
Habermann et al, J. Neurochemistry, 1998, 51:522-527.
Kryzhanovskii et al, Bull. Exp. Biol. Med., Jan. 1975, 77/7:732-736.
Matsuda et al, Biochemical and Biophysical Research Communications, Jan. 29, 1982, 104/2:799-805.
Rabasseda et al, Toxicon, 1988, 26/4:329-336.
Aguilera et al, J. Neurochemistry, 1991, 56:733-738.
Bigalke et al, Naunyn-Schmiedeberg's Arch. Pharamcol., 1981, 316:544-251.
Korolkiewicz et al, Pharmacological Research, 1998, 37/6:477-483.
Kryzhanovskii et al, Bulletin of Exptal. Biology and Medicine, 1961, 52/11:35-43.
Sanofi Pasteur, Inc. Product Information, Tetanus Toxoid Adsorbed, 2005, pp. 1-5.
Pellizzari et al, Phil. Trans. R. Soc. Lond., 1999, 354:259-268.
Rethy et al, Lancet, 1997, 350/9090:1518.
Ahnert-Hilger et al, Progress in Neurobiology, 1995, 46:83-96.
Niemann et al, Behring Institute Mitteilungen, 1991, 89:153-162 abstract only.
Schantz et al, Microbiological Reviews, 1992, 56/1:80-99.
Demain et al, Vaccine, 2005, 23:5420-5423.
Turton et al, TRENDS in Biochemical Sciences, 2002, 27/11:552-558.
Grumelli et al, NeuroToxicology, 2005, 26:761-767.
Dokmetjian et al, Vaccine, 2000, 18:2698-2703.
Gaber et al, J. R. Soc. Med., 2005, 98:63.
Journal of Biological Standardization, 1973, 1, 203-213.
Dolimbek et al, Immunol. Invest., Aug.-Nov. 2002, 31(3-4):247-262 Abstract only.
Behr Omri M.
Minnifield N. M
LandOfFree
Methods for using tetanus toxin for beneficial purposes in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using tetanus toxin for beneficial purposes in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using tetanus toxin for beneficial purposes in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074430